Literature DB >> 3261709

Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation.

T A Poulton1, A Gallagher, R C Potts, J S Beck.   

Abstract

Phytohaemagglutinin (PHA)-stimulated peripheral blood lymphocytes were examined sequentially for changes in volume, the appearance of cell membrane receptors and nucleic acid synthesis. The kinetics of appearance of activation antigens were compared with the progress of the cell through the separate events of volume growth and nucleic acid syntheses, to determine points at which regulation of receptors may control further progress through the cell cycle. In all samples tested there was a consistent pattern of response in the proportion of cells progressing through the cell cycle. Most of the T cells increased in size (mean 82% at 24 hr), fewer cells entered the Gla/Glb phase with the onset of RNA synthesis (mean 68% at 48 hr) and even fewer entered DNA synthesis (mean 42% at 72 hr). The time-course of appearance and the number of cells expressing IL-2 receptors were almost identical with that of cells responding by RNA synthesis. A similar correlation was observed between expression of the transferrin receptor and DNA synthesis. Addition of anti-Tac antibody temporarily suppressed the onset of RNA synthesis and antibodies to the transferrin receptor suppressed DNA synthesis. These linkages are further evidence that IL-2 and transferrin are the specific signals for cellular RNA and DNA synthesis. With optimal concentrations of PHA, addition of IL-2 did not increase the proportion of cells bearing activation antigens or undergoing nucleic acid synthesis. Suboptimal concentrations of PHA produced a small reduction in the number of cells expressing the IL-2 receptor, but a much greater reduction in the rate of entry into RNA synthesis. There was a consistent increase in all activation parameters tested with the addition of IL-2, but the proportion of cells expressing the transferrin receptor and entering DNA synthesis was consistently lower than that of cells that expressed the IL-2 receptor or entered RNA synthesis. This suggests that regulation of the IL-2 receptor is not responsible for the reduction in the number of cells that proceed to proliferation. The CD2 antigen (T11(1] showed increasing expression in a step-wise fashion after activation, the increases coinciding with the onset of RNA and DNA syntheses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261709      PMCID: PMC1385052     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Modesl of growth in mammalian cells.

Authors:  W K Sinclair; D W Ross
Journal:  Biophys J       Date:  1969-08       Impact factor: 4.033

2.  Lymphokine regulation of activated (G1) lymphocytes. II. Glucocorticoid and anti-Tac-induced inhibition of human T lymphocyte proliferation.

Authors:  F Bettens; F Kristensen; C Walker; U Schwuléra; G D Bonnard; A L de Weck
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

3.  A new method of testing for mitogen-induced lymphocyte stimulation: measurement of the percentage of growing cells and of some aspects of their cell kinetics with an electronic particle counter.

Authors:  J H Gibbs; R A Brown; A J Robertson; R C Potts; J S Beck
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

4.  Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes.

Authors:  B F Haynes; M E Hemler; D L Mann; G S Eisenbarth; J Shelhamer; H S Mostowski; C A Thomas; J L Strominger; A S Fauci
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  Some tetracycline drugs suppress mitogen-stimulated lymphocyte growth but others do not.

Authors:  R C Potts; A MacConnachie; R A Brown; J H Gibbs; A J Robertson; H A Hassan; J S Beck
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

6.  Human lymphocyte proliferation. I. Correlation between activated and proliferating T-lymphocytes.

Authors:  F Kristensen; C Walker; F Joncourt; F Bettens; A L de Weck
Journal:  Immunol Lett       Date:  1982-08       Impact factor: 3.685

7.  The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.

Authors:  Y M Hussein; M A Kerr; J S Beck
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

8.  Human trophoblast cell-surface antigens defined by monoclonal antibodies.

Authors:  M Lipinski; D R Parks; R V Rouse; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2.

Authors:  L M Neckers; J Cossman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

10.  Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content.

Authors:  T Cotner; J M Williams; L Christenson; H M Shapiro; T B Strom; J Strominger
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  16 in total

1.  Lymphocyte subsets and their proliferation in a model for a delayed-type hypersensitivity reaction in the skin.

Authors:  F J Fritz; R Pabst; R M Binns
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

2.  Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.

Authors:  Anna-Maria A De Costa; Corinne A Schuyler; David D Walker; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2011-11-25       Impact factor: 6.968

3.  Activation markers and cell proliferation as indicators of toxicity: a flow cytometric approach.

Authors:  A Johannisson; A Thuvander; I L Gadhasson
Journal:  Cell Biol Toxicol       Date:  1995-12       Impact factor: 6.691

4.  Altered T cell responses in children with autism.

Authors:  Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac N Pessah; Judy Van de Water
Journal:  Brain Behav Immun       Date:  2010-09-15       Impact factor: 7.217

5.  Effect of major burns on early and late activating markers of peripheral blood T lymphocytes.

Authors:  S Sayed; R Bakry; M El-Shazly; M El-Oteify; S Terzaki; M Fekry
Journal:  Ann Burns Fire Disasters       Date:  2012-03-31

6.  Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.

Authors:  Aditya Ambade; Patrick Lowe; Karen Kodys; Donna Catalano; Benedek Gyongyosi; Yeonhee Cho; Arvin Iracheta-Vellve; Adeyinka Adejumo; Banishree Saha; Charles Calenda; Jeeval Mehta; Eric Lefebvre; Pamela Vig; Gyongyi Szabo
Journal:  Hepatology       Date:  2019-02-12       Impact factor: 17.425

7.  Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations.

Authors:  Anthony J Smith; Peter R Meyer; Deshratn Asthana; Margarita R Ashman; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro.

Authors:  C Giordano; R De Maria; M Todaro; G Stassi; A Mattina; P Richiusa; G Galluzzo; F Pantó; A Galluzzo
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

9.  Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells.

Authors:  M Qian; G Chandrasena; R J Ho; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes.

Authors:  A C van der Wal; J J Piek; O J de Boer; K T Koch; P Teeling; C M van der Loos; A E Becker
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.